Damora Therapeutics, Inc.
DMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDamora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The $1.30B market capitalization puts DMRA squarely in small-cap range for its industry. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Market Cap
$1.30B
Beta
1.44
P/E (TTM)
—
P/E (Fwd)
-9.71
EPS (TTM)
$-0.25
EPS (Fwd)
$-2.17
ROE
-99.7%
ROA
-21.6%
Cash
$540.5M
Total Debt
$0
Free CF
-$16.0M
52W Change
187.1%
Annual Financials
Cash vs Debt
Where DMRA stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, DMRA finished 18.23% below its 150-day moving average ($25.78) and 18.74% below its 200-day moving average ($25.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMRA overbought or oversold?
At the October 12, 2026 close, DMRA's RSI(14) was 38.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Damora Therapeutics, Inc. reports $540.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$16.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -99.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Damora Therapeutics, Inc. and its sector.